Stock Price
107.57
Daily Change
0.42 0.39%
Monthly
-24.68%
Yearly
57.01%
Q2 Forecast
106.95

Insmed reported $305.96M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
DBV Technologies USD 2.77M 1.31M Sep/2025
Gilead Sciences USD 7B 930M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026